

**Finance questions**  
**Costing: National COVID-19 Vaccine Program - Novavax vaccine cancellation**  
**NPP: Adjusting the COVID-19 Vaccine Supply Portfolio**

**12 September 2024 questions**

Assumptions tab

Cell	Finance Question	Health response
s47C, s47E(d)		
Rows 8-49, Rows 56-77	Can you please explain each dose delivery table. Is the top one renegotiated doses and the bottom current agreement doses?	Bottom table is the current delivery schedule. Top table is the proposed delivery schedule.
F77, F49	Pending answer to the above, we note the difference between the current doses (34.4m?) and future doses (28.6m?) is 5.867m doses. Can you please explain this figure and how it relates to the 7.5m doses cancelled and 2.3m doses remaining.	Note there was an error in the costing (cells F12 and F13 – which changes F49 to 26.9m). 34.4m less 26.9m is 7.504m doses (cancelled doses).

**PROTECTED**

**FOI 25-26/027 - Document 10**

F60, F12	Why is there a difference between the Q4 2022 doses in these two tables?	This was an error, they should be the same. See response to above question.
	Please confirm that the 2.83m doses which were going to be delivered 2025 will now be spread from 2025 to 2029?	Correct. See column H in the attached titled "Response to Finance Questions – Row 2 – Novavax History 17 Sept.xlsx".
	What are 'replacement' doses? Are these for a different expiry or variant (e.g. JN.1?)	The draft Advance Purchase Agreement (APA) amendment includes a substitution clause to ensure Australia is provided with the most updated vaccine and protection against COVID-19. Replacement doses will be of the latest variant or strain that conforms to the latest recommendation of the World Health Organization at the time.
H31	Is payment required in 2026-27 for all doses out to 2029? If so, why has this approach been taken rather than payment more closely associated with delivery?	Payment is required for the shortfall for the Q3 2026 doses from credits from pre-payments of cancelled doses, which the APA provides must be used to pay for future invoices. We are currently in active negotiations with Novavax to cancel some additional doses, to achieve an outcome where the amounts of the known credits and the amounts of the future invoices are equal.
H2	Can you please confirm why this exchange rate was used, what source is used and what date?	Exchange rate of the 2023-24 MYEFO approved EV was used as this is the exchange rate that makes up the current budget estimates. Also for transparency to be able to see financial effect of cancelling doses. Seeking confirmation from DoF whether a different exchange rate should be used.

**PROTECTED**